Proliferation and tissue remodeling in cancer: The hallmarks revisited

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Markert, E K ^a   Levine, A J ^a,b   Vazquez, A ^a,b  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cancer metabolism; Cancer pathways; Cancer stem cell; Hallmarks; Meta pathway

Indexed keywords

GLYCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SERINE;

AMINO ACID METABOLISM; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; METABOLISM; ONCOGENE MYC; ONCOGENE RAS; OVARY CANCER; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE REMODELING; TUMOR SUPPRESSOR GENE; UPREGULATION;

CELL PROLIFERATION; CLUSTER ANALYSIS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; NEOPLASMS; NF-KAPPA B; OXIDATIVE PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870560047     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.140     Document Type: Article

References (49)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Fritz V, Fajas L. Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 29: 4369-4377.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
4. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
6. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472.
7. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009; 34: 881-895.
8. Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 80: 114-144.
9. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science (80-) 2006; 314: 268-274.
10. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
11. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
12. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
13. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 107: 22745-22750.
14. Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA. 2011; 108: 21276-21281.
15. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
16. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A et al. Epithelialmesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28: 1435-1445.
17. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S et al. Epithelialmesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293-299.
18. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
19. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell 2012; 149: 656-670.
20. Hart GW, Copeland RJ. Glycomics hits the big time. Cell 2010; 143: 672-676.
21. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011; 14: 443-451.
22. Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010; 8: e1000514.
23. Vazquez A, Markert EK, Oltvai ZN. Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS One 2011; 6: e25881.
24. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-350.
25. Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, Sara H et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 2011; 125: 421-430.
26. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-874.
27. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLos One 2008; 3: e2888.
28. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 2010; 107: 22745-22750.
29. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY et al. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 1063-1070.
30. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000; 227: 271-278.
31. Stojkovic M, Lako M, Strachan T, Murdoch A. Derivation, growth and applications of human embryonic stem cells. Reproduction 2004; 128: 259-267.
32. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
33. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-197.
34. Anjomshoaa A, Lin YH, Black MA, McCall JL, Humar B, Song S et al. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer 2008; 99: 966-973.
35. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS et al. EMT is the dominant program in human colon cancer. BMC Med Genomics 2011; 4: 9.
36. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005; 102: 3738-3743.
37. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6: 99-106.
38. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008; 99: 1884-1890.
39. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3: e47.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
41. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005; 102: 13550-13555.
42. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569.
43. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4: R69.
44. Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, Marty S et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 2007; 25: 961-973.
45. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009; 37: 4587-4602.
46. Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK, Young RA. Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA. 2006; 103: 5899-5904.
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102: 15545-15550.
48. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008; 26: 4078-4085.
49. Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 2010; 26: 456-463.